Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis.

ABSTRACT: Environmental factors, mucosal permeability and defective immunoregulation drive overactive immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic products rationally designed to complement missing or underrepresented functions in the dysbiotic microbiome of IBD patients, address upstream targets, rather than targeting a single cytokine to block downstream inflammation responses. GUT-103, composed of 17 strains that synergistically provide protective and sustained engraftment in the IBD inflammatory environment, prevented and treated chronic immune-mediated colitis. Therapeutic application of GUT-108 reversed established colitis in a humanized chronic T cell-mediated mouse model. It decreased pathobionts

SUBMITTER: van der Lelie D 

PROVIDER: S-EPMC8163890 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature